Observed Signal · Sep 11, 2026 · Market Signal · Source: Johnson & Johnson · Impact: 4/5
New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026
Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC. Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ and prophylactic strategies.
Track Johnson & Johnson Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival,...
REGENXBIO Presents Positive 3-Year Data for Sura-vec in Diabetic Retinopathy
REGENXBIO Inc. announced positive three-year durability data from the Phase II ALTITUDE study of its investigational gene therapy surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy (DR), presented at the Retina Society 59th Annual Scientific Meeting. The data showed that a majority of Dose Level 3 participants with non-proliferative DR (NPDR) achieved a >2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) at three years after a single, in-office suprachoroidal injection, with no vision-threatening events and no additional treatment for DR. No intraocular inflammation (IOI) was observed with short-course prophylactic topical steroids. These results support the potential of sura-vec as a one-time treatment that could reduce the burden of repeat injections for patients.
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.